Skip to main content

Tumor-Induced Osteomalacia

Calcified Tissue International volume 108, pages 128–142 (2021)Cite this article

Abstract

Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome caused by tumoral production of fibroblast growth factor 23 (FGF23). The hallmark biochemical features include hypophosphatemia due to renal phosphate wasting, inappropriately normal or frankly low 1,25-dihydroxy-vitamin D, and inappropriately normal or elevated FGF23. TIO is caused by typically small, slow growing, benign phosphaturic mesenchymal tumors (PMTs) that are located almost anywhere in the body from the skull to the feet, in soft tissue or bone. The recent identification of fusion genes in a significant subset of PMTs has provided important insights into PMT tumorigenesis. Although management of this disease may seem straightforward, considering that complete resection of the tumor leads to its cure, locating these often-tiny tumors is frequently a challenge. For this purpose, a stepwise, systematic approach is required. It starts with thorough medical history and physical examination, followed by functional imaging, and confirmation of identified lesions by anatomical imaging. If the tumor resection is not possible, medical therapy with phosphate and active vitamin D is indicated. Novel therapeutic approaches include image-guided tumor ablation and medical treatment with the anti-FGF23 antibody burosumab or the pan-FGFR tyrosine kinase inhibitor, BGJ398/infigratinib. Great progress has been made in the diagnosis and treatment of TIO, and more is likely to come, turning this challenging, debilitating disease into a gratifying cure for patients and their providers.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

References

  1. Drezner MK, Feinglos MN (1977) Osteomalacia due to 1alpha, 25-dihydroxycholecalciferol deficiency. Association with a giant cell tumor of bone. J Clin Investig 60(5):1046–1053

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Minisola S et al (2017) Tumour-induced osteomalacia. Nat Rev Dis Primers 3:17044

    Article  PubMed  Google Scholar 

  3. Florenzano P, Gafni RI, Collins MT (2017) Tumor-induced osteomalacia. Bone Rep 7:90–97

    Article  PubMed  PubMed Central  Google Scholar 

  4. Prader A et al (1959) Rickets following bone tumor. Helv Paediatr Acta 14:554–565

    CAS  PubMed  Google Scholar 

  5. White KE et al (2001) The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting. J Clin Endocrinol Metab 86(2):497–500

    Article  CAS  PubMed  Google Scholar 

  6. ADHR Consortium (2000) Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 26(3):345–348

    Article  CAS  Google Scholar 

  7. Shimada T et al (2001) Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 98(11):6500–6505

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Jonsson KB et al (2003) Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 348(17):1656–1663

    Article  CAS  PubMed  Google Scholar 

  9. Folpe AL et al (2004) Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol 28(1):1–30

    Article  PubMed  Google Scholar 

  10. Shimada T et al (2004) FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19(3):429–435

    Article  CAS  PubMed  Google Scholar 

  11. Endo I et al (2015) Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment. Endocr J 62(9):811–816

    Article  CAS  PubMed  Google Scholar 

  12. Jiang Y et al (2012) Tumor-induced osteomalacia: an important cause of adult-onset hypophosphatemic osteomalacia in China: report of 39 cases and review of the literature. J Bone Miner Res 27(9):1967–1975

    Article  PubMed  Google Scholar 

  13. Jung GH et al (2010) A 9-month-old phosphaturic mesenchymal tumor mimicking the intractable rickets. J Pediatr Orthop B 19(1):127–132

    Article  PubMed  Google Scholar 

  14. Crossen SS et al (2017) Tumor-induced osteomalacia in a 3-year-old with unresectable central giant cell lesions. J Pediatr Hematol Oncol 39(1):e21–e24

    Article  PubMed  Google Scholar 

  15. Fernández-Cooke E et al (2015) Tumor-induced rickets in a child with a central giant cell granuloma: a case report. Pediatrics 135(6):e1518–e1523

    Article  PubMed  Google Scholar 

  16. Chong WH et al (2013) Tumor localization and biochemical response to cure in tumor-induced osteomalacia. J Bone Miner Res 28(6):1386–1398

    Article  CAS  PubMed  Google Scholar 

  17. Tella SH et al (2017) Multimodality image-guided cryoablation for inoperable tumor-induced osteomalacia. J Bone Miner Res 32(11):2248–2256

    Article  CAS  PubMed  Google Scholar 

  18. Li X et al (2019) Nonremission and recurrent tumor-induced osteomalacia: a retrospective study. J Bone Miner Res 35:469–477

    Article  PubMed  CAS  Google Scholar 

  19. Peterson NR, Summerlin DJ, Cordes SR (2010) Multiple phosphaturic mesenchymal tumors associated with oncogenic osteomalacia: case report and review of the literature. Ear Nose Throat J 89(6):E11–E15

    PubMed  Google Scholar 

  20. Arai R et al (2017) A rare case of multiple phosphaturic mesenchymal tumors along a tendon sheath inducing osteomalacia. BMC Musculoskelet Disord 18(1):79

    Article  PubMed  PubMed Central  Google Scholar 

  21. Riminucci M et al (2003) FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Investig 112(5):683–692

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Toro L et al (2018) Erythropoietin induces bone marrow and plasma fibroblast growth factor 23 during acute kidney injury. Kidney Int 93(5):1131–1141

    Article  CAS  PubMed  Google Scholar 

  23. Rabadi S et al (2018) Acute blood loss stimulates fibroblast growth factor 23 production. Am J Physiol Ren Physiol 314(1):F132–F139

    Article  CAS  Google Scholar 

  24. Bhattacharyya N et al (2012) Fibroblast growth factor 23: state of the field and future directions. Trends Endocrinol Metab 23(12):610–618

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Miyamoto K et al (2011) Sodium-dependent phosphate cotransporters: lessons from gene knockout and mutation studies. J Pharm Sci 100(9):3719–3730

    Article  CAS  PubMed  Google Scholar 

  26. Blau JE, Collins MT (2015) The PTH-Vitamin D-FGF23 axis. Rev Endocr Metab Disord. https://doi.org/10.1007/s11154-015-9318-z

    Article  PubMed  Google Scholar 

  27. Burnett SM et al (2006) Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res 21(8):1187–1196

    Article  CAS  PubMed  Google Scholar 

  28. Clinkenbeard EL et al (2017) Erythropoietin stimulates murine and human fibroblast growth factor-23, revealing novel roles for bone and bone marrow. Haematologica 102(11):e427–e430

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Daryadel A et al (2018) Erythropoietin stimulates fibroblast growth factor 23 (FGF23) in mice and men. Pflugers Arch 470(10):1569–1582

    Article  CAS  PubMed  Google Scholar 

  30. Hanudel MR et al (2018) Effects of erythropoietin on fibroblast growth factor 23 in mice and humans. Nephrol Dial Transplant 34:2057–2065

    Article  PubMed Central  CAS  Google Scholar 

  31. Weidner N (1991) Review and update: oncogenic osteomalacia-rickets. Ultrastruct Pathol 15(4–5):317–333

    Article  CAS  PubMed  Google Scholar 

  32. Drezner MK (2001) Tumor-induced osteomalacia. Rev Endocr Metab Disord 2(2):175–186

    Article  CAS  PubMed  Google Scholar 

  33. Folpe AL (2019) Phosphaturic mesenchymal tumors: a review and update. Semin Diagn Pathol 36(4):260–268

    Article  PubMed  Google Scholar 

  34. Weidner N, Santa Cruz D (1987) Phosphaturic mesenchymal tumors. A polymorphous group causing osteomalacia or rickets. Cancer 59(8):1442–1454

    Article  CAS  PubMed  Google Scholar 

  35. Wu H et al (2018) Phosphaturic mesenchymal tumor with an admixture of epithelial and mesenchymal elements in the jaws: clinicopathological and immunohistochemical analysis of 22 cases with literature review. Mod Pathol 32:189–204

    Article  PubMed  CAS  Google Scholar 

  36. Harvey JN, Gray C, Belchetz PE (1992) Oncogenous osteomalacia and malignancy. Clin Endocrinol (Oxf) 37(4):379–382

    Article  CAS  Google Scholar 

  37. Ogose A et al (2001) Recurrent malignant variant of phosphaturic mesenchymal tumor with oncogenic osteomalacia. Skelet Radiol 30(2):99–103

    Article  CAS  Google Scholar 

  38. Rico H et al (1986) Oncogenous osteomalacia: a new case secondary to a malignant tumor. Bone 7(5):325–329

    Article  CAS  PubMed  Google Scholar 

  39. Uramoto N, Furukawa M, Yoshizaki T (2009) Malignant phosphaturic mesenchymal tumor, mixed connective tissue variant of the tongue. Auris Nasus Larynx 36(1):104–105

    Article  PubMed  Google Scholar 

  40. Wyman AL, Paradinas FJ, Daly JR (1977) Hypophosphataemic osteomalacia associated with a malignant tumour of the tibia: report of a case. J Clin Pathol 30(4):328–335

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Yavropoulou MP et al (2018) Distant lung metastases caused by a histologically benign phosphaturic mesenchymal tumor. Endocrinol Diabetes Metab Case Rep 2018:18–0023

    PubMed Central  Google Scholar 

  42. Sidell D et al (2011) Malignant phosphaturic mesenchymal tumor of the larynx. Laryngoscope 121(9):1860–1863

    PubMed  Google Scholar 

  43. Bergwitz C et al (2011) Case records of the Massachusetts General Hospital. Case 33-2011. A 56-year-old man with hypophosphatemia. N Engl J Med 365(17):1625–1635

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Carter JM et al (2015) A novel chromogenic in situ hybridization assay for FGF23 mRNA in phosphaturic mesenchymal tumors. Am J Surg Pathol 39(1):75–83

    Article  PubMed  Google Scholar 

  45. Houang M et al (2013) Phosphaturic mesenchymal tumors show positive staining for somatostatin receptor 2A (SSTR2A). Hum Pathol 44(12):2711–2718

    Article  CAS  PubMed  Google Scholar 

  46. Bahrami A et al (2009) RT-PCR analysis for FGF23 using paraffin sections in the diagnosis of phosphaturic mesenchymal tumors with and without known tumor induced osteomalacia. Am J Surg Pathol 33(9):1348–1354

    Article  PubMed  Google Scholar 

  47. Yamada Y et al (2018) Histopathological and genetic review of phosphaturic mesenchymal tumours, mixed connective tissue variant. Histopathology 72(3):460–471

    Article  PubMed  Google Scholar 

  48. Weidner N et al (1985) Neoplastic pathology of oncogenic osteomalacia/rickets. Cancer 55(8):1691–1705

    Article  CAS  PubMed  Google Scholar 

  49. Jan de Beur SM et al (2002) Localisation of mesenchymal tumours by somatostatin receptor imaging. Lancet 359(9308):761–763

    Article  CAS  PubMed  Google Scholar 

  50. Lee JC et al (2015) Identification of a novel FN1-FGFR1 genetic fusion as a frequent event in phosphaturic mesenchymal tumour. J Pathol 235(4):539–545

    Article  CAS  PubMed  Google Scholar 

  51. Lee JC et al (2016) Characterization of FN1-FGFR1 and novel FN1-FGF1 fusion genes in a large series of phosphaturic mesenchymal tumors. Mod Pathol 29(11):1335–1346

    Article  CAS  PubMed  Google Scholar 

  52. Agaimy A et al (2017) Phosphaturic mesenchymal tumors: clinicopathologic, immunohistochemical and molecular analysis of 22 cases expanding their morphologic and immunophenotypic spectrum. Am J Surg Pathol 41(10):1371–1380

    Article  PubMed  Google Scholar 

  53. Sent-Doux KN et al (2018) Phosphaturic mesenchymal tumor without osteomalacia: additional confirmation of the “nonphosphaturic” variant, with emphasis on the roles of FGF23 chromogenic in situ hybridization and FN1-FGFR1 fluorescence in situ hybridization. Hum Pathol 80:94–98

    Article  CAS  PubMed  Google Scholar 

  54. Shiba E et al (2016) Immunohistochemical and molecular detection of the expression of FGF23 in phosphaturic mesenchymal tumors including the non-phosphaturic variant. Diagn Pathol 11:26

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  55. Wasserman JK et al (2016) Phosphaturic mesenchymal tumor involving the head and neck: a report of five cases with FGFR1 fluorescence in situ hybridization analysis. Head Neck Pathol 10(3):279–285

    Article  PubMed  PubMed Central  Google Scholar 

  56. Lyles KW et al (1980) Hypophosphatemic osteomalacia: association with prostatic carcinoma. Ann Intern Med 93(2):275–278

    Article  CAS  PubMed  Google Scholar 

  57. Mak MP et al (2012) Advanced prostate cancer as a cause of oncogenic osteomalacia: an underdiagnosed condition. Support Care Cancer 20(9):2195–2197

    Article  PubMed  Google Scholar 

  58. Nakahama H et al (1995) Prostate cancer-induced oncogenic hypophosphatemic osteomalacia. Urol Int 55(1):38–40

    Article  CAS  PubMed  Google Scholar 

  59. Reese DM, Rosen PJ (1997) Oncogenic osteomalacia associated with prostate cancer. J Urol 158(3 Pt 1):887

    Article  CAS  PubMed  Google Scholar 

  60. Savva C et al (2019) Oncogenic osteomalacia and metastatic breast cancer: a case report and review of the literature. J Diabetes Metab Disord 18(1):267–272

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Sauder A et al (2016) FGF23-associated tumor-induced osteomalacia in a patient with small cell carcinoma: a case report and regulatory mechanism study. Int J Surg Pathol 24(2):116–120

    Article  CAS  PubMed  Google Scholar 

  62. Lin HA et al (2014) Ovarian cancer-related hypophosphatemic osteomalacia—a case report. J Clin Endocrinol Metab 99(12):4403–4407

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Abate EG et al (2016) Tumor induced osteomalacia secondary to anaplastic thyroid carcinoma: a case report and review of the literature. Bone Rep 5:81–85

    Article  PubMed  PubMed Central  Google Scholar 

  64. Jin X et al (2013) Osteomalacia-inducing renal clear cell carcinoma uncovered by 99mTc-hydrazinonicotinyl-Tyr3-octreotide (99mTc-HYNIC-TOC) scintigraphy. Clin Nucl Med 38(11):922–924

    Article  PubMed  Google Scholar 

  65. van Heyningen C et al (1994) Oncogenic hypophosphataemia and ectopic corticotrophin secretion due to oat cell carcinoma of the trachea. J Clin Pathol 47(1):80–82

    Article  PubMed  PubMed Central  Google Scholar 

  66. Taylor HC, Fallon MD, Velasco ME (1984) Oncogenic osteomalacia and inappropriate antidiuretic hormone secretion due to oat-cell carcinoma. Ann Intern Med 101(6):786–788

    Article  CAS  PubMed  Google Scholar 

  67. Reinert RB, Bixby D, Koenig RJ (2018) Fibroblast growth factor 23-induced hypophosphatemia in acute leukemia. J Endocr Soc 2(5):437–443

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Elderman JH, Wabbijn M, de Jongh F (2016) Hypophosphataemia due to FGF-23 producing B cell non-Hodgkin’s lymphoma. BMJ Case Rep. https://doi.org/10.1136/bcr-2015-213954

    Article  PubMed  PubMed Central  Google Scholar 

  69. Wasserman H et al (2016) Two case reports of FGF23-induced hypophosphatemia in childhood biliary atresia. Pediatrics. https://doi.org/10.1542/peds.2015-4453

    Article  PubMed  PubMed Central  Google Scholar 

  70. Feng J et al (2017) The diagnostic dilemma of tumor induced osteomalacia: a retrospective analysis of 144 cases. Endocr J 64(7):675–683

    Article  PubMed  Google Scholar 

  71. Collins MT et al (2020) Chapter 64. Tumor-induced osteomalacia. Academic, New York, pp 1539–1552

    Google Scholar 

  72. Chong WH et al (2011) Tumor-induced osteomalacia. Endocr Relat Cancer 18(3):R53–R77

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Kane SV et al (2018) Phosphaturic mesenchymal tumor of the nasal cavity and paranasal sinuses: a clinical curiosity presenting a diagnostic challenge. Auris Nasus Larynx 45(2):377–383

    Article  PubMed  Google Scholar 

  74. Jan de Beur SM (2005) Tumor-induced osteomalacia. JAMA 294(10):1260–1267

    Article  PubMed  Google Scholar 

  75. Allgrove J, Shaw NJ (2015) A practical approach to vitamin D deficiency and rickets. Endocr Dev 28:119–133

    Article  CAS  PubMed  Google Scholar 

  76. Endo I et al (2008) Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement. Bone 42(6):1235–1239

    Article  CAS  PubMed  Google Scholar 

  77. Francis F et al (1995) A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. Nat Genet 11(2):130–136

    Article  CAS  Google Scholar 

  78. Feng JQ et al (2006) Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 38(11):1310–1315

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Levy-Litan V et al (2010) Autosomal-recessive hypophosphatemic rickets is associated with an inactivation mutation in the ENPP1 gene. Am J Hum Genet 86(2):273–278

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Haffner D et al (2019) Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nat Rev Nephrol 15(7):435–455

    Article  PubMed  PubMed Central  Google Scholar 

  81. Lim YH et al (2014) Multilineage somatic activating mutations in HRAS and NRAS cause mosaic cutaneous and skeletal lesions, elevated FGF23 and hypophosphatemia. Hum Mol Genet 23(2):397–407

    Article  CAS  PubMed  Google Scholar 

  82. Konishi K et al (1991) Hypophosphatemic osteomalacia in von Recklinghausen neurofibromatosis. Am J Med Sci 301(5):322–328

    Article  CAS  PubMed  Google Scholar 

  83. Saville PD et al (1955) Osteomalacia in Von Recklinghausen’s neurofibromatosis; metabolic study of a case. Br Med J 1(4925):1311–1313

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. White KE et al (2005) Mutations that cause osteoglophonic dysplasia define novel roles for FGFR1 in bone elongation. Am J Hum Genet 76(2):361–367

    Article  CAS  PubMed  Google Scholar 

  85. Brownstein CA et al (2008) A translocation causing increased α-Klotho level results in hypophosphatemic rickets and hyperparathyroidism. Proc Natl Acad Sci USA 105(9):3455–3460

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Yang M et al (2019) Molecular imaging in diagnosis of tumor-induced osteomalacia. Curr Probl Diagn Radiol 48(4):379–386

    Article  PubMed  Google Scholar 

  87. Seufert J et al (2001) Octreotide therapy for tumor-induced osteomalacia. N Engl J Med 345(26):1883–1888

    Article  CAS  PubMed  Google Scholar 

  88. Breer S et al (2014) 68Ga DOTA-TATE PET/CT allows tumor localization in patients with tumor-induced osteomalacia but negative 111In-octreotide SPECT/CT. Bone 64:222–227

    Article  CAS  PubMed  Google Scholar 

  89. El-Maouche D et al (2016) Ga-DOTATATE for tumor localization in tumor-induced osteomalacia. J Clin Endocrinol Metab 101(10):3575–3581

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Takeuchi Y et al (2004) Venous sampling for fibroblast growth factor-23 confirms preoperative diagnosis of tumor-induced osteomalacia. J Clin Endocrinol Metab 89(8):3979–3982

    Article  CAS  PubMed  Google Scholar 

  91. Andreopoulou P et al (2011) Selective venous catheterization for the localization of phosphaturic mesenchymal tumors. J Bone Miner Res 26(6):1295–1302

    Article  PubMed  Google Scholar 

  92. Dadoniene J et al (2016) Tumour-induced osteomalacia: a literature review and a case report. World J Surg Oncol 14(1):4

    Article  PubMed  PubMed Central  Google Scholar 

  93. Piemonte S et al (2014) Six-year follow-up of a characteristic osteolytic lesion in a patient with tumor-induced osteomalacia. Eur J Endocrinol 170(1):K1–K4

    Article  CAS  PubMed  Google Scholar 

  94. Colangelo L et al (2018) A challenging case of tumor-induced osteomalacia: pathophysiological and clinical implications. Calcif Tissue Int 103(4):465–468

    Article  CAS  PubMed  Google Scholar 

  95. Clunie GP, Fox PE, Stamp TC (2000) Four cases of acquired hypophosphataemic (‘oncogenic’) osteomalacia. Problems of diagnosis, treatment and long-term management. Rheumatology (Oxf) 39(12):1415–1421

    Article  CAS  Google Scholar 

  96. Sun ZJ et al (2015) Surgical treatment of tumor-induced osteomalacia: a retrospective review of 40 cases with extremity tumors. BMC Musculoskelet Disord 16:43

    Article  PubMed  PubMed Central  Google Scholar 

  97. Hautmann AH et al (2015) Tumor-induced osteomalacia: an up-to-date review. Curr Rheumatol Rep 17(6):512

    Article  PubMed  CAS  Google Scholar 

  98. Tarasova VD et al (2013) Successful treatment of tumor-induced osteomalacia due to an intracranial tumor by fractionated stereotactic radiotherapy. J Clin Endocrinol Metab 98(11):4267–4272

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  99. Mishra SK et al (2019) Successful management of tumor-induced osteomalacia with radiofrequency ablation: a case series. JBMR Plus 3(7):e10178

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  100. Huang QL, Feig DS, Blackstein ME (2000) Development of tertiary hyperparathyroidism after phosphate supplementation in oncogenic osteomalacia. J Endocrinol Investig 23(4):263–267

    Article  CAS  Google Scholar 

  101. Gupta A et al (2004) FGF-23 is elevated by chronic hyperphosphatemia. J Clin Endocrinol Metab 89(9):4489–4492

    Article  CAS  PubMed  Google Scholar 

  102. Geller JL et al (2007) Cinacalcet in the management of tumor-induced osteomalacia. J Bone Miner Res 22(6):931–937

    Article  CAS  PubMed  Google Scholar 

  103. Ovejero D et al (2017) Octreotide is ineffective in treating tumor-induced osteomalacia: results of a short-term therapy. J Bone Miner Res 32(8):1667–1671

    Article  CAS  PubMed  Google Scholar 

  104. Paglia F, Dionisi S, Minisola S (2002) Octreotide for tumor-induced osteomalacia. N Engl J Med 346(22):1748–1749; author reply 1748–1749

  105. Jan De Beur S et al (2019) OR13-1 burosumab improves the biochemical, skeletal, and clinical symptoms of tumor-induced osteomalacia syndrome. J Endocr Soc. https://doi.org/10.1210/js.2019-OR13-1

    Article  PubMed Central  Google Scholar 

  106. Wohrle S et al (2011) FGF receptors control vitamin D and phosphate homeostasis by mediating renal FGF-23 signaling and regulating FGF-23 expression in bone. J Bone Miner Res 26(10):2486–2497

    Article  CAS  PubMed  Google Scholar 

  107. Wohrle S et al (2013) Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets. J Bone Miner Res 28(4):899–911

    Article  PubMed  CAS  Google Scholar 

  108. Collins MT et al (2015) Striking response of tumor-induced osteomalacia to the FGFR inhibitor NVP-BGJ398. In: American Society of Bone and Mineral Research annual meeting 2015, Seattle, WA

  109. Fumarola C et al (2019) Expanding the arsenal of FGFR inhibitors: a novel chloroacetamide derivative as a new irreversible agent with anti-proliferative activity against FGFR1-amplified lung cancer cell lines. Front Oncol 9:179

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Endocrinology Department, School of Medicine, Pontificia Universidad Católica de Chile, Av. Diagonal Paraguay 362, Cuarto piso, Santiago, Chile

    Pablo Florenzano & Macarena Jimenez

  2. Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA

    Iris R. Hartley

  3. Skeletal Disorders and Mineral Homeostasis Section, National Institutes of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, USA

    Iris R. Hartley, Kelly Roszko, Rachel I. Gafni & Michael T. Collins

  4. Skeletal Disorders and Mineral Homeostasis Section, NIDCR, NIH, 30 Convent Drive, Building 30, Room 228, MSC 4320, Bethesda, MD, 20892-4320, USA

    Michael T. Collins

Authors
  1. Pablo Florenzano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Iris R. Hartley
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Macarena Jimenez
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kelly Roszko
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rachel I. Gafni
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Michael T. Collins
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Pablo Florenzano or Michael T. Collins.

Ethics declarations

Conflict of interest

The NIDCR receives financial support from QED Pharma to study BGJ398 in tumor-induced osteomalacia. The Pontificia Universidad Católica de Chile (PF, MJ) receives research support from Ultragenyx Pharmaceutical, Inc. for research related to hypophosphatemic rickets. Work in the Laboratories of IH, KR, RG, MC is supported by the Intramural Research Program of the NIH, NIDCR.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Florenzano, P., Hartley, I.R., Jimenez, M. et al. Tumor-Induced Osteomalacia. Calcif Tissue Int 108, 128–142 (2021). https://doi.org/10.1007/s00223-020-00691-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00223-020-00691-6

Keywords

  • Tumor-induced osteomalacia
  • FGF23
  • Hypophosphatemia